%0 Journal Article
%T Comparison of quality of life after bladder augmentation in patients previously treated with intradetrusor botulinum toxin A for neurogenic detrusor overactivity.
%A Bakali Issaui Z
%A Truong XQ
%A Genon M
%A Gaillet S
%A Tournebise H
%A Zini P
%A Bernuz B
%A Thiry Escudier I
%A Bardot P
%A Radot C
%A Muro C
%A Lenne Aurier K
%A Bonopera R
%A De Brier G
%A Boissier R
%A Lechevallier E
%A Karsenty G
%A Michel F
%J Fr J Urol
%V 34
%N 10
%D 2024 Jul 24
%M 39059768
暂无%R 10.1016/j.fjurol.2024.102706
%X <B>OBJECTIVE: </B>To compare the quality of life (QoL) in the same patients first treated with botulinum toxin A (BTA) injections for neurogenic detrusor overactivity (NDO) and then with bladder augmentation (BA).<BR><B>METHODS: </B>Retrospective study of patients who had BA after BTA treatment between January 2012 and December 2022. Qualiveen Short Form questionnaires and a 7-level Likert/PGI-I scale to answer the question "How would you describe your quality of life after surgery compared to when you felt your best with BTA injections?" were collated and analyzed.<BR><B>RESULTS: </B>Fifty-two BAs for neurogenic bladder (NDO or low compliance) were performed in patients with a median age of 43years [33; 52] previously treated with BTA. After a median follow-up of 33.5 [13.8; 54.3] months, the median Qualiveen-SF global score after BA was significantly higher than that obtained at best BTA efficacy (1.63 [1; 2.63] vs. 2.63 [1.88; 3], P=0.012), as were the scores for the fear, constraints/restrictions and limitations/inconvenience domains. The median PGI-I score was +3 [2; 3] (truly better QoL) and 85.4% of patients reported a QoL after BA superior to the best QoL under BTA.<BR><B>CONCLUSIONS: </B>BA provides a greater range of QoL improvement than BTA injection for patients who have experienced both treatments. Long-lasting effects and absence of need to perform iterative retreatment were the main reasons.<BR><B>METHODS: </B>